Ed Reznik, PhD

Associate Attending, Computational Oncologist

Ed Reznik, PhD

Associate Attending, Computational Oncologist
Share
Share
Ed Reznik

Office Phone

646-608-7553

Education

Boston University

Ed Reznik is an Associate Attending Computational Oncologist in the Department of Epidemiology and Biostatistics, and is affiliated with the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and the Urology Service. His research applies computational and informatic approaches to address basic and translational questions in mitochondrial genetics and metabolic dysregulation in cancer. The long-term goal of his research program is understanding how metabolic phenomena support the initiation, progression, and therapeutic susceptibility of tumors. Originally trained as an engineer, he has applied tools from optimization theory to develop predictive, genome-scale models of bacterial and eukaryotic metabolism from high-throughput metabolic data. Using data from The Cancer Genome Atlas Consortium, Dr. Reznik produced the first large-scale assessment of mitochondrial DNA copy number variation across solid tumor types. In parallel, he has developed integrative informatic approaches to study solid tumor metabolism through analysis of metabolomic and transcriptomic data, including the publication of the first atlas of metabolomic changes across tumor types. He is also an active member of the Kidney Cancer Working Group and contributes to the analysis of genomic, metabolomic, and immunological data related to kidney cancer biology and management.

Publications

Selected peer-reviewed publications:

  1. Xie AX, Tansey W*, Reznik E*. UnitedMet harnesses RNA-metabolite covariation to impute metabolite levels in clinical samples. Nat Cancer. 2025 Apr 18. doi: 10.1038/s43018-025-00943-0. Epub ahead of print. PMID: 40251399.
  2. Zucker M, Perry MA, Gould SI, Elkrief A, Safonov A, Thummalapalli R, Mehine M, Chakravarty D, Brannon AR, Ladanyi M, Razavi P, Donoghue MTA, Murciano-Goroff YR, Grigoriadis K, McGranahan N, Jamal-Hanjani M, Swanton C, Chen Y, Shen R, Chandarlapaty S, Solit DB, Schultz N, Berger MF, Chang J, Schoenfeld AJ, Sánchez-Rivera FJ, Reznik E*, Bandlamudi C*. Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer. Cell. 2025 Feb 6;188(3):851-867.e17. doi: 10.1016/j.cell.2024.11.010. Epub 2024 Dec 18. PMID: 39701102; PMCID: PMC11922039.
  3. Tang C, Castillon VJ, Waters M, Fong C, Park T, Boscenco S, Kim S, Pekala K, Carrot-Zhang J, Hakimi AA, Schultz N, Ostrovnaya I, Gusev A, Jee J*, Reznik E*. Obesity-dependent selection of driver mutations in cancer. Nat Genet. 2024 Nov;56(11):2318-2321. doi: 10.1038/s41588-024-01969-3. Epub 2024 Oct 28. PMID: 39468367; PMCID: PMC11549034.
  4. Kim M, Gorelick AN, Vàzquez-García I, Williams MJ, Salehi S, Shi H, Weiner AC, Ceglia N, Funnell T, Park T, Boscenco S, O’Flanagan CH, Jiang H, Grewal D, Tang C, Rusk N, Gammage PA, McPherson A, Aparicio S, Shah SP*, Reznik E*. Single-cell mtDNA dynamics in tumors is driven by coregulation of nuclear and mitochondrial genomes. Nat Genet. 2024 May;56(5):889-899. doi: 10.1038/s41588-024-01724-8. Epub 2024 May 13. PMID: 38741018; PMCID: PMC11096122.
  5. Mahmood M, Liu EM, Shergold AL, Tolla E, Tait-Mulder J, Huerta-Uribe A, Shokry E, Young AL, Lilla S, Kim M, Park T, Boscenco S, Manchon JL, Rodríguez-Antona C, Walters RC, Springett RJ, Blaza JN, Mitchell L, Blyth K, Zanivan S, Sumpton D, Roberts EW, Reznik E*, Gammage PA*. Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma. Nat Cancer. 2024 Apr;5(4):659-672. doi: 10.1038/s43018-023-00721-w. Epub 2024 Jan 29. PMID: 38286828; PMCID: PMC11056318.
  6. Tang C, Xie AX, Liu EM, Kuo F, Kim M, DiNatale RG, Golkaram M, Chen YB, Gupta S, Motzer RJ, Russo P, Coleman J, Carlo MI, Voss MH, Kotecha RR, Lee CH, Tansey W, Schultz N, Hakimi AA, Reznik E. Immunometabolic coevolution defines unique microenvironmental niches in ccRCC. Cell Metab. 2023 Aug 8;35(8):1424-1440.e5. doi: 10.1016/j.cmet.2023.06.005. Epub 2023 Jul 5.
  7. Benedetti E, Liu EM, Tang C, Kuo F, Buyukozkan M, Park T, Park J, Correa F, Hakimi AA, Intlekofer AM, Krumsiek J, Reznik E. A multimodal atlas of tumour metabolism reveals the architecture of gene-metabolite covariation. Nat Metab. 2023 Jun;5(6):1029-1044. doi: 10.1038/s42255-023-00817-8. Epub 2023 Jun 19. PMID: 37337120; PMCID: PMC10290959.
  8. Gorelick AN, Kim M, Chatila WK, La K, Hakimi AA, Berger MF, Taylor BS, Gammage PA*, Reznik E*. Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA. Nat Metab. 2021 Apr;3(4):558-570. doi: 10.1038/s42255-021-00378-8. Epub 2021 Apr 8. PMID: 33833465; PMCID: PMC9304985.
  9. Gorelick AN, Sánchez-Rivera FJ, Cai Y, Bielski CM, Biederstedt E, Jonsson P, Richards AL, Vasan N, Penson AV, Friedman ND, Ho YJ, Baslan T, Bandlamudi C, Scaltriti M, Schultz N, Lowe SW, Reznik E*, Taylor BS*. Phase and context shape the function of composite oncogenic mutations. Nature. 2020 Jun;582(7810):100-103. doi: 10.1038/s41586-020-2315-8. Epub 2020 May 27. PMID: 32461694; PMCID: PMC7294994.

View a full listing of Ed Reznik’s journal articles.